[
    {
        "id": "osp-9842",
        "type": "article-journal",
        "title": "Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review",
        "author": [
            {
                "family": "Shofa",
                "given": "Nyimas Maida"
            },
            {
                "family": "Mudjari",
                "given": "Nurike Setiyari"
            },
            {
                "family": "Ekawati",
                "given": "Rusdiyana"
            },
            {
                "family": "Arianti",
                "given": "Arianti"
            },
            {
                "family": "Mufida",
                "given": "Annisa Zahra"
            },
            {
                "family": "Widodo",
                "given": "Budi"
            },
            {
                "family": "Sugihartono",
                "given": "Titong"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/adalimumab-therapy-for-crohn-s-disease-and-axial-spondyloarthritis-in-latent-tuberculosis-a-bibliometric-systematic-literature-review",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2026
                ]
            ]
        },
        "container-title": "Sultan Qaboos University Medical Journal",
        "volume": "26",
        "issue": "1",
        "page": "171-183",
        "DOI": "10.18295/2075-0528.2971",
        "publisher": "Sultan Qaboos University",
        "ISSN": "2075-051X",
        "abstract": "The management of Crohn’s disease (CD) using anti-tumour necrosis factor therapy in tuberculosis (TB)-endemic regions poses major clinical challenges due to the risk of latent TB infection reactivation. This bibliometric–systematic literature review synthesised evidence from 17 peer-reviewed studies (2020–2025) evaluating adalimumab administered with concurrent prophylactic antitubercular therapy. Thematic synthesis and bibliometric mapping using VOSviewer demonstrated that adalimumab achieved 60–85% clinical remission in moderate-to-severe CD and axial spondyloarthritis while enhancing mucosal healing. However, 1–3% of patients developed active TB despite appropriate screening and isoniazid prophylaxis, revealing false-negative diagnostics and partial chemoprophylaxis protection. These findings highlight the need for region-specific frameworks integrating multimodal screening, targeted prophylaxis and ongoing clinical surveillance. Adalimumab remains a cornerstone biologic in TB-endemic settings, but its safe use requires adaptive, context-driven protocols emphasising vigilant risk mitigation."
    }
]